恩威医药 (301331.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(恩威医药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年第三季度2024年第二季度2024年第一季度2023年第四季度2023年第三季度2023年第二季度2023年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 172,191,555.13204,673,609.76183,475,935.51215,306,218.06174,636,712.20194,447,972.09200,800,387.47
 营业收入(元) 172,191,555.13204,673,609.76183,475,935.51215,306,218.06174,636,712.20194,447,972.09200,800,387.47
二、营业总成本(元) 169,260,689.93191,491,971.29174,117,084.98200,948,340.83164,905,296.50164,331,174.61168,140,196.62
 营业成本(元) 88,039,293.0095,537,602.5091,259,994.06101,184,846.9889,017,282.5398,385,290.0494,153,241.28
 研发费用(元) 2,402,926.981,750,570.331,617,199.721,849,849.686,898,509.635,940,068.552,127,675.84
 营业税金及附加(元) 2,980,956.633,926,124.012,539,956.523,292,563.382,313,734.282,521,960.682,764,536.66
 销售费用(元) 55,625,310.6471,181,204.7060,898,593.7675,480,163.3654,636,944.6745,715,433.1459,019,548.45
 管理费用(元) 20,865,007.4119,053,344.1718,208,330.9720,151,571.3413,780,810.3713,550,605.9111,951,249.51
 财务费用(元) -652,804.7343,125.58-406,990.05-1,010,653.91-1,741,984.98-1,782,183.71-1,876,055.12
  其中:利息费用(元) 907,388.89424,394.37144,375.00----
  其中:利息收入(元) 1,595,585.42645,669.58590,393.231,033,827.821,762,786.481,828,860.911,936,297.59
 资产减值损失(元) -46,481.97-641,106.21-538,016.26-289,514.08132,205.5117,166.68-39,381.04
 信用减值损失(元) 1,169,731.23-1,298,512.61-383,154.611,190,934.28-381,499.32-530,271.54-682,514.46
三、其他经营收益
 加:投资收益(元) 551,565.04791,634.281,057,229.31865,794.12817,950.06993,361.751,065,912.13
  其中:对联营企业和合营企业的投资收益(元) -49,558.69--10,291.997,554.70--
 资产处置收益(元) -44,847.47-43,356.80-78,567.23223.30---41,203.90
 其他收益(元) 623,410.19866,238.221,076,220.52727,847.67573,262.379,265,872.881,174,435.23
四、营业利润(元) 5,184,242.2212,856,535.3510,492,562.2616,853,162.5210,873,334.3239,862,927.2534,137,438.81
 加:营业外收入(元) 205,564.48--7,946.26266,455.66-10,073.57
 减:营业外支出(元) 2,805,079.41416,792.10571.95677,997.87503.32--
五、利润总额(元) 2,584,727.2912,445,864.4510,491,990.3116,183,110.9111,139,286.6639,844,837.8134,147,512.38
 减:所得税费用(元) -1,502,792.562,935,351.712,068,060.322,805,825.812,166,338.473,552,425.656,477,882.62
六、净利润(元) 4,087,519.859,510,512.748,423,929.9913,377,285.108,972,948.1936,292,412.1627,669,629.76
(一)按经营持续性分类
  持续经营净利润(元) 4,087,519.859,510,512.748,423,929.9913,377,285.108,972,948.1936,292,412.1627,669,629.76
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 4,087,519.859,510,512.748,423,929.9913,377,285.108,972,948.1936,292,412.1627,669,629.76
 扣除非经常性损益后的净利润(元) 5,268,576.058,494,280.976,680,192.8912,604,867.617,596,555.5027,590,374.3325,793,201.95
七、每股收益
 一、基本每股收益(元) 0.040.050.120.190.130.520.39
 二、稀释每股收益(元) 0.040.050.120.190.130.520.39
九、综合收益总额(元) 4,087,519.859,510,512.748,423,929.9913,377,285.108,972,948.1936,292,412.1627,669,629.76
 归属于母公司所有者的综合收益总额(元) 4,087,519.859,510,512.748,423,929.9913,377,285.108,972,948.1936,292,412.1627,669,629.76
公告日期 2024-10-242024-08-302024-04-222024-04-222023-10-272023-08-282023-04-22
审计意见(境内) 标准无保留意见

前瞻产业研究院